Christiane Querfeld, M.D., Ph.D.
At the end of the day, it is always about helping patients get better so they can go on to continue living normal lives.
American Board of Dermatology, Dermatopathology
American Board of Dermatology, Dermatology
1994, Ph.D., University of Heidelberg, Germany
1994, M.D., University of Cologne, Germany
2010-2011, Dermatopathology, Northwestern University, Chicago, IL
2002-2006, Cutaneous Lymphoma, Northwestern University, Chicago, IL
2007-2010, Residency, Dermatology, University of Chicago, Chicago, IL
2006-2007, Internship, Department of Medicine, Johns Hopkins University, Good Samaritan Hospital, Baltimore, MD
2022-present, Professor, Division of Dermatology, Department of Surgery, Division of Dermatology, Department of Pathology, and Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2019-2022, Associate Professor, Division of Dermatology, Department of Surgery, Division of Dermatology, Department of Pathology, and Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2014-present, Director, Cutaneous Lymphoma Program, Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA
2017-2020, Chief, Division of Dermatology, Department of Surgery. City of Hope, Duarte, CA
2014-2019, Assistant Professor, Division of Dermatology, Department of Surgery, Department of Pathology, and Department of Hematology & Hematopoietic Cell transplantation
2011-2014, Assistant Attending Physician, Dermatology, Memorial Hospital for Cancer & Allied Disease, New York, NY
2011-2014, Assistant Member, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Christiane Querfeld, M.D., Ph.D., is an associate professor in dermatology and dermatopathology, and member of Beckman Research Institute of City of Hope. She is director of City of Hope's multidisciplinary Cutaneous Lymphoma Program. Her current clinical and laboratory research has focused on investigations of the biology of cutaneous lymphomas and novel therapies for these diseases. Dr. Querfeld's innovative research targets both the malignancy and the surrounding cells in the tumor's microenvironment. The immune cells in the tumor microenvironment when activated have the capacity to kill the lymphoma cells. Her laboratory is advancing novel strategies to both activate the immune response against CTCL as well as direct killing of the cancer. She and her multidisciplinary team has already developed successful well tolerated interventions with meaningful benefits for her patients.
Young Investigator Award, Northwestern Memorial Foundation
Young Investigator Award, Cutaneous Lymphoma Foundation
Chicago Dermatological Society Research Award, Chicago Dermatological Society
Celgene Future Leader in Hematology Award, Celgene
Junior Investigator Research Development Award from the Young Innovators Fund, City of Hope
Excellence Award, City of Hope
STOP CANCER - Research Career Development Award
Clinical Scholar Career Development Award, Leukemia & Lymphoma Society
Board of Directors, International Society of Cutaneous Lymphomas
United States Cutaneous Lymphoma Consortium
Diplomat, American Academy of Dermatology
Society for Investigative Dermatology
American Society of Dermatopathology
American Society of Hematology
Querfeld C, Leung S, Myskowski PL, Curran SA, Goldman DA, Heller G, Wu X, Kil SH, Sharma S, Finn K, Mehrara B, Horwitz S, Moskowitz A, Rosen ST, Halpern AC, Young JW. Primary T-cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile. Cancer Immunol Res. 2018. DOI: 10.1158/2326-6066.CIR-17-0270.
Marchetti MA, Pulitzer MP, Myskowski PL, Lunning MA, Dusza SW, Horwitz SM, Moskowitz AJ, Querfeld C. Cutaneous manifestations of human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: a single-center, retrospective study. J Am Acad Dermatol (accepted for publication), 2014.
Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM. Results of an open-label multicenter phase II trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood 123(8): 1159-1166, 2014.
Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary Cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome) Part II. Prognosis, management, and future directions. J Am Acad Dermatol 70(2): 223.e1-17; quiz 240-2, 2014.
Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome) Part I. Diagnosis: Clinical and histopathologic features, and new molecular and biologic markers. J Am Acad Dermatol 70(2): 205.e1-16; quiz 221-2, 2014.
Pulitzer M, Myskowski MP, Horwitz S, Querfeld C, Li J, Murali R. Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors. Pathology 46(7): 610-616, 2014.
Li JY, Guitart J, Pulitzer M, Subtil A, Sundram U, Kim YH, Deonizio J, Myskowski PL, Moskowitz A, Horwitz S, Querfeld C. Multicenter case series of indolent small/medium-sized CD8+ lymphoid proliferations with predilection for the ear and face. Am J Dermatopathol 36(5): 402-408, 2014.
Li JY, Pulitzer M, Myskowski PL, Dusza SW, Horwitz S, Moskowitz A, Querfeld C. A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides. J Am Acad Dermatol 69(3): 366-374.e4, 2013.
Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel TM, Campbell K, Geskin L. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Photodermatol Photoimmunol Photomed 28(5): 250-257, 2012.
Thomas TO, Agrawal P, Guitart J, Rosen ST, Rademaker AW, Querfeld C, Hayes JP, Kuzel TM, Mittal BB. Outcome of patients with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 85(3):747-53, 2013.
Li JY, Horwitz S, Moskowitz A, Myskowski PL, Pulitzer M, Querfeld C. Management of cutaneous T-cell lymphoma: new and emerging targets and treatment options. Cancer Manag Res 4: 75-89, 2012.
Querfeld C, Rosen ST, Guitart J, Rademaker A, Pezen DS, Dolan E, Baron J, Yarosh DB, Foss F, Kuzel TM. Multicenter phase II trial of temozolomide in mycosis fungoides/Sézary syndrome: correlation with O6-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res 17(17): 5748-5754, 2011.
Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A, Rook AH, Mark LA, Pinter-Brown L, Hamid O, Lin B, Bian Y, Boye M, Day JM, Rosen ST. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymph 52(8): 1474-1480, 2011.
Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson L, Pinter-Brown L, Advani R, Parker S, Kim E, Junkins-Hopkins J, Foss F, Cacchio P, Duvic M. Sézary Syndrome: evaluation, immuno-pathogenesis, literature review of therapeutic options and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64(2): 352-404, 2011.
Gerami P, Wickless SC, Querfeld C, Rosen ST, Kuzel TM, Guitart J. Cutaneous involvement with marginal zone lymphoma. J Am Acad Dermatol 63(1): 142-145, 2010.
Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology (Williston Park) 24(7): 574-587, 2010.
Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, Gerami P, Kuzel TM. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single center experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymph 50(12): 1969-1976, 2009.
Querfeld C, Rosen ST, Guitart J, Rademaker A, Foss F, Gupka R, Kuzel TM. Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 56(4): 580-3, 2007.
Querfeld C, Kuzel TM, Guitart J, Rizvi M, Sabharwal SS, Krett N, Rosen ST. The selective protein kinase C ? inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 126(7): 1641-7, 2006.
Querfeld C, Rosen ST, Kuzel TM, Kirby KA, Roenigk HH Jr, Prinz BM, Guitart J. Long-term follow-up of patients with early stage cutaneous T-cell lymphoma who achieved complete remission on psoralen plus UV-A monotherapy. Arch Dermatol 141(3): 305-11, 2005.
Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung SB, Posten W, Kuzel TM. Comparison of selective RAR and RXR retinoid mediated efficacy, tolerance, and survival in refractory cutaneous T-cell lymphoma. J Am Acad Dermatol 51(1): 25-32, 2004.
This is a list of 21 representative publications (selected from 81 publications).